JinkoSolar Subsidiary Estimates Up to $1.1 Billion Unaudited Net Loss for Full Year 2025, Signaling Significant Financial Headwinds
Summary
JinkoSolar's majority-owned subsidiary, Jiangxi Jinko, estimates a preliminary unaudited net loss of RMB5.9 billion to RMB6.9 billion (approximately $819 million to $958 million USD) for full year 2025, with non-GAAP losses potentially exceeding $1 billion, signaling significant financial distress.
Key Events
-
Subsidiary Estimates Significant Net Loss
Jinko Solar Co., Ltd. (Jiangxi Jinko), JinkoSolar's majority-owned principal operating subsidiary, estimates a preliminary unaudited net loss attributable to shareholders in the range of RMB5,900 million to RMB6,900 million for the full year ended December 31, 2025. This translates to approximately $819 million to $958 million USD (using an exchange rate of 7.2 RMB/USD).
-
Non-GAAP Loss Even Higher
Excluding extraordinary gains and losses, Jiangxi Jinko's preliminary unaudited net loss is estimated to be in the range of RMB6,700 million to RMB7,800 million, or approximately $930 million to $1.08 billion USD.
-
Accounting Differences Noted
The filing explicitly states that these preliminary results for Jiangxi Jinko are prepared under PRC GAAP and differ from JinkoSolar's consolidated financials (prepared under US GAAP), advising investors not to solely rely on these figures. JinkoSolar holds approximately 55.59% equity interest in Jiangxi Jinko.
Analysis
JinkoSolar's principal operating subsidiary, Jiangxi Jinko, has reported preliminary unaudited net losses for full year 2025 that are extremely substantial relative to the parent company's market capitalization. While these results are for the subsidiary only, prepared under PRC GAAP, and differ from JinkoSolar's consolidated US GAAP financials, a loss of this magnitude from a majority-owned operating entity indicates severe financial underperformance. Investors should be highly concerned about the potential impact on JinkoSolar's upcoming consolidated results and overall financial health. The company's warning not to solely rely on these preliminary figures underscores the complexity, but the underlying operational challenges are clear.
At the time of this filing, JKS was trading at $25.83 on NYSE in the Manufacturing sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $13.42 to $31.88. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.